Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Galapagos and Merck & Co have agreed to end strategic alliances signed in 2008 and 2009, covering metabolic, cardiovascular and inflammatory diseases.
Subscribe to our email newsletter
Subsequently, Galapagos has regained worldwide rights for all assets developed in its strategic alliances with Merck & Co, through an affiliate.
Merck will make a payment of EUR12m to Galapagos for work completed in 2010.
Including this, Galapagos will have received a total of EUR20.9m in upfront and milestone payments derived from the alliances.
Galapagos CEO Onno van de Stolpe said in the alliances with Merck, they have discovered promising targets and developed target discovery assays for diseases with considerable unmet medical needs.
"Galapagos now owns these valuable assets which can form the basis for future alliances," Stolpe said.
Merck External Discovery and Preclinical Sciences senior vice president Kathleen Metters said changes in their early discovery strategy have required them to make some challenging decisions and they look forward to investigating alternate opportunities to collaborate with Galapagos in the future.